Three ways to work with the FDA for better patient-focused trials

Putting patients at the center of drug development allows us to design more efficient clinical trials that yield better data about a product’s risks and benefits. Companies that collaborate with the FDA can get direct feedback on their methodology and help build consensus on patient-relevant outcomes that might be accepted as proof of efficacy and safety.

This article covers three useful practices for getting the most out of your collaboration.


Open PDF

Return to Insights Center

Related Insights

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

3 ways to incorporate DE&I in your communications strategy

Sep 29, 2021

Blog

Actigraphy advances a patient-first approach: Reduce patient burden — and make the most of valuable data

Oct 15, 2021

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Video

Overcoming asset transfer challenges during a merger and acquisition (M&A)

Oct 20, 2021

Video

Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Blog

Biosimilar Development: Are therapeutic clinical trials needed?

Nov 16, 2021